Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) and keeping the price target at ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

The age of de-extinction may soon be a reality. Advances in genetic engineering and synthetic biology are making resurrecting ...

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Cancer is a terrifying diagnosis. The second-leading cause of death in the United States drains $25 trillion a year from the ...

While we think first of editing the human genome to cure diseases, CRISPR could play an important part in fighting global warming too. Indeed, an example given by Doudna herself in an interview about ...

Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...